Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
batiraxcept + nab-paclitaxel + gemcitabine
- Development stage
- Unknown
- Lead developer
- Aravive
- Modality
- Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
This is a combination therapy consisting of batiraxcept (AVB-S6-500), nab-paclitaxel, and gemcitabine. - **Batiraxcept** is a recombinant fusion protein (Fc-fusion) that binds to and neutralizes GAS6, inhibiting AXL receptor signaling, a pathway implicated in tumor growth and resistance to therapy. - **Nab-paclitaxel** is a nanoparticle albumin-bound formulation of paclitaxel, a cytotoxic agent that stabilizes microtubules, disrupting mitosis in cancer cells. - **Gemcitabine** is a nucleoside analog that inhibits DNA synthesis, primarily used as an antineoplastic agent. This specific triple combination is under investigation primarily for the treatment of advanced or metastatic pancreatic cancer, aiming to improve outcomes over the established nab-paclitaxel plus gemcitabine regimen by adding targeted inhibition of the GAS6/AXL pathway.
- Other names
- AVB-S6-500 + nab-paclitaxel + gemcitabine
02
Targets
AXL (AXL receptor tyrosine kinase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on batiraxcept + nab-paclitaxel + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on batiraxcept + nab-paclitaxel + gemcitabine.